• AusCann’s 50:50 joint venture, DayaCann, plants its second medicinal cannabis crop in Chile
• Planting of the crop follows the recent granting of its second cultivation licence by the Chilean government
• DayaCann presently holds the only cultivation licence to be issued in Chile
• Harvest of the crop is expected to commence in the first half of 2018 and is to be processed into trial formulations for the treatment of chronic and neuropathic pain
• Planting represents another positive milestone in establishing a fully integrated medical cannabis supply chain in Latin America
• This complements and diversifies the work being undertaken in Australia to develop a fully integrated medical cannabis supply chain to provide final dose form medications to Australian patients
AusCann Group Holdings Ltd (ASX:AC8 or ‘the Company’) is pleased to announce that its 50:50 Chilean joint venture, DayaCann, has commenced planting of its second medicinal cannabis crop, following the grant of its cultivation licence as announced on 22 November 2017.
For further information please download PDF attached:
Download this document
